Earlier studies reported that ANXA3, ANXA2, and its pseudogene ANXA2P2 are overexpressed in various cancers, including prostate cancer, and facilitated transcription of the stemness genes Nanog, Sox2, and Oct4 (51–53). This evidence concerns the gene ANXA2P2 and prostate carcinoma.